ABSTRACTS (e-)POSTER PRESENTATIONS
P20 Results of laparoscopic splenectomy for benign and malignant hemopathies
D. Bron, A. Salaroli, N. Meuleman, M. Maerevoet, M. Vercruyssen, C. Spilleboudt, A. De Wind, G. Dapri, G.B. Cadiere, B. Cadiere
P38 Coexistence of inversion (16) et Bcr-Abl rearrangement in acute myeloid leulemia: a clinical description
J. Devreux, G. Di Prinzio, S. Bailly, S. Lefebvre, G. Verstraete, K. van Renterghem, A. Charlot, P. Saussoy, J-P. Defour, N. Straetmans, X. Poiré, L. Michaux, M-C. Vekemans, V. Havelange
P37 CD123 expression on acute leukemia blasts, hematogones, and monocytes; used as Minimal Residual Disease Marker
L. Rozen, L. Mekkaoui, C. Rassart, A. Janssens, D. Bron, A. Ferster, B. Cantinieaux
P36 Next generation sequencing in patients with therapy-related myeloid neoplasms
H. Claerhout, E. Lierman, D. Kieffer, N. Boeckx
P35 In-house developed 15-gene sequencing panel for acute myeloid leukemia and myelodysplasia allows robust detection of genetic defects including FLT3-ITD and CEBPA mutations
B. Denys, J. Van der Meulen, E. de Latter, S. Lefever, T. Rosseel, W. Steyaert, G. Vandercruyssen, I. Rottiers, D. Creytens, J. Van Dorpe, F. Speleman, B. Poppe, N. Van Roy, K. de Leeneer, K. Claes, K. Vandepoele
P24 Flowcytometric detection of aberrant intraepithelial lymphocytes in refractory celiac disease
N. Boeckx, G. Verhoef, M. Hiele
P23 Monoclonal gammopathy of clinical significance: about a case of pulmonary nodular amyloidosis
G. Di Prinzio, J. Devreux, S. Lefebvre, S. Bailly, G. Verstraete, A. Bourgois, C. Pedreira, J-P. Defour, A. Camboni, A. Marchandise, T. Pieters, M-C. Vekemans
P22 Case report: Richter syndrome with plasmablastic lymphoma
A. Ladang, M. Simul, J. Somja, J. Foguenne, A. Gothot, A. Keutgens, F. Tassin
P21 Bone marrow necrosis with E. coli marrow invasion in a patient with secondary diffuse large B-cell lymphoma : a rare cause of pancytopenia
A. Delie, M. Hofmans, P. Vlummens
P39 Respiratory illness in hematologic disorders: try to think of Pulmonary Alveolar Proteinosis and GATA-2.
A. Camboni, C. Dachelet, E. Van den Neste, L. Sacre, L. Marot
P19 Vanishing bile duct syndrome associated with diffuse large B-cell lymphoma
G. Dachy, T. Connerotte
P18 Early discontinuation of lenalidomide in patients with relapsing or refractory multiple myeloma: predictive factors for stopping in the real life
A. Pistone, M. Maerevoet, S. Wittnebel, M. Vercruyssen, S. Buntinx, C. Spilleboudt, D. Bron, N. Meuleman
P17 Diagnostic strength of bone marrow aspirate versus biopsy in (smoldering) multiple myeloma patients
P. Vlummens, F. Offner
P16 Real-Life Experience with Brentuximab Vedotin (Adcetris®): the Belgian National Registry
G. Verhoef, M. André, J. Imschoot, P. Graas, D. Bron
P15 Treatment patterns of Waldenström’s macroglobulinemia in Belgium
A. Smet, V. Van Hende, M. André, C. Bonnet, G. Bries, V. De Wilde, H. Demuynck, N. Meuleman, W. Schroyens, A. Van Hoof, M. Giordan, L. de Vos, A. Janssens
P14 The impact of the updated IMWG diagnostic criteria in a real-life SMM cohort: a single center experience
P. Vlummens, F. Offner
P13 Monoclonal Gammopathy of Undetermined Significance (MGUS) after kidney transplantation: prevalence and clinical significance
B. Heymans, D. Dierickx, B. Sprangers
P12 The glycan-binding galectin-1 is involved in osteoclast biology
J. Muller, M. Binsfeld, S. Dubois, G. Carmeliet, Y. Beguin, R. Heusschen, J. Caers
P61 A deadly sore throat: acquired-TTP or Clindamycin induced thrombotic microangiopathy
A. Papaleo, M. Libertalis, M. Vekemans
P79 Atypical bone pain after allogeneic bone marrow transplantation for myelofibrosis
G. Verstraete, S. Lefevre, S. Bailly, G. Di Prinzio, J. Devreux, J-P. Defour, P. D’Abadie, P. Van Eeckhout, F. Kino, C. Goemare, N. Lepage, L. Michaux, V. Havelange, E. Van den Neste, C. Lambert, L. Knoops, M-C. Vekemans, X. Poiré
P78 Outcome of patients with hepatic sinusoidal obstruction syndrome admitted in the intensive care unit
A. Jaspers
P77 High dose therapy and autologous stem cell transplantation in gynaecological malignancies: a monocentric retrospective study
M. Nderlita, I. Vergote, D. Dierickx
P76 PrimeFlow™ RNA Assay: a novel technique for single-cell expression analysis in heterogeneous cell populations
B. Depreter, M. Meul, B. Denys, B. De Moerloose, E. Terras, K. Vandepoele, J. Philippé, T. Lammens
P75 Implementation of Releasing Time to Care - the Productive Hematology Ward
E. Boon, H. Bolckmans, K. Bal, S. Slootmans, A.L. van de Velde, A. Devos
P64 Hemolytic anemia in a progressive breast cancer: think about thrombotic microangiopathy and treat the cancer
S. Bailly, M-C. Vekemans, B. Chatelain, M. André, T. Vander Borght, L. D’Hondt, L. Faugeras, G. Verstraete, J. Devreux, G. Di Prinzio, S. Lefevre
P63 Follicular dendritic cell sarcoma: report of a case and review of the literature
V. Galle, S. Verbeke, W. Ceelen, I. Moors
P62 Absence of fragmented red cells (FRC) measured on Sysmex XN® could be useful to exclude FRC presence on blood smears
V.T.P. Nguyen, H. Kandet, R. Li, B. Cantinieaux
P11 Low-pass sequencing of plasma cell DNA and of circulating cell-free DNA for the detection of copy number aberrations and early response monitoring in multiple myeloma
B. Dewaele, S. Smits, L. Dehaspe, N. Brison, J. Ding, J. Van Houdt, H. Lemmens, L. Michaux, J. Vermeesch, P. Vandenberghe
P60 A rare case of ‘Thrombocytosis’
F.M. Maerevoet, M. Elouaaliti, A. Cantinieaux, M. Spilleboudt, M. Vercruyssen, D. Bron, N. Meuleman
P59 Automatic clustering of cell populations characterized by immunophenotyping
C. Gosset, J. Foguenne, M. Simul, A. Keutgens, F. Tassin, A. Gothot
P58 Extremely elevated C - reactive protein: a bad omen for haematological patients?
L. Tryssesoone, D. Deeren
P57 Comparison of the a-Globin StripAssay® and MLPA® as a diagnostic tool for a-thalassaemia
H. Claerhout, J. Oosterbosch, C.L. Harteveld, E. Lierman, D. Kieffer
P56 Evaluation of Four Hemoglobin Separation Analyzers for Hemoglobinopathy Diagnosis
S. Degandt, R. Coens, K.V. van Maele, N. Verplancke, B. Cauwelier, H. Devos, M. Langlois, J. Emmerechts
P41 A 54-year-old woman with a myeloid neoplasm associated with eosinophilia and t(5;12) (q33;p13)/PDGRFB rearrangement: case report and mini-review of the literature
Q. Delefortrie, F. Lambert, G. Bulliard, M. Jurdan, S. Toffoli, D. Sartenaer, S. De Prophetis, D. Pranger, A. Kornreich, P. Mineur
P40 Successful initial treatment of a cytopenic AML patient with pulmonary leukemic infiltration at diagnosis
I. Moors, P. Vlummens, C. Lecluyse, J. Vermassen
PP01 Mucosal- associated invariant T cells deficiency in multiple myeloma can be overcome by PD-1 inhibition
M. Favreau, K. Venken, S. Faict, K. Maes, K. De Veirman, E. De Bruyne, X. Leleu, D. Elewaut, K. Vanderkerken, E. Menu
PP33 Targeted next-generation sequencing using a pan-myeloid panel in myelodysplastic neoplasms: implementation in clinical diagnostics
G. Froyen, J. Willemse, A. Broekmans, R. Smets, B. Cruys, N. Put, V. Madoe, M. Janssen, O. Soepenberg, G. Bries, B. Maes
PP32 Retrospective real-world data confirms the efficacy and safety of decitabine in treating patients with acute myeloid leukemia in Belgium
B. Malfait, J. Braakman, L. de Vos, B. Bailly, I. Vande Broek, S. Meers, D. Dierickx
PP31 Roles of microRNAs in myeloid malignancies driven by activated tyrosine kinases
M. Claus, A. Essaghir, P. Saussoy, L. Michaux, J.B. Demoulin, V. Havelange
PP30 Retrospective study of de novo and secondary myeloid sarcoma
S. van Aelst, H. Claerhout, C. Melis, T. Tousseyn, P. Vandenberghe, D. Dierickx, N. Boeckx
PP05 The detection rate of PET/CT after co-administration of [18F]NaF and [18F]FDG is superior to the detection rate of whole-body MRI in the diagnosis of MM lesions
J. Caers, N. Withofs, F. Cousin, T. Tancredi, P. Simoni, B. De Prijck, K. Hafraoui, C. Bonnet, R. Heusschen, V. Alvarez-Miezentseva, R. Hustinx, Y. Beguin
PP04 Light chain IgLV3-21 is associated with poor prognosis in Chronic Lymphocytic Leukemia patients independently of the presence of heavy chain IgHV3-21
B. Stamatopoulos, T. Smith, D. Sims, A. Heger, H. Dreau, A. Schuh
PP03 The anaphase-promoting-complex/ cyclosome: a new promising target in mantle cell lymphoma and diffuse large B cell lymphoma
A. Maes, E. De Smedt, K. De Veirman, K. Maes, E. Menu, E. Van Valckenborgh, K. Vanderkerken, E. De Bruyne
PP02 The histone methyltransferases G9a/GLP: new promising targets for the treatment of multiple myeloma
E. De Smedt, J. Devin, H. Liu, A. Maes, K. Maes, K. De Veirman, E. Menu, K. Vanderkerken, J. Moreaux, E. De Bruyne
PP34 The MLL partial tandem duplication (MLL-PTD) is correlated with WT1 overexpression in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and shows a similar expression profile during treatment
K. Vandepoele, B. Denys
PP71 Impact of Tofacitinib on xenogeneic graft versus host disease
M. Hannon, C. Grégoire, J. Muller, G. Fransolet, L. Delens, Y. Beguin, G. Ehx, F. Baron
P10 The genetic landscape of the murine 5T models for multiple myeloma
K. Maes, B. Boeckx, L. De Beck, E. Menu, K. De Veirman, K. Vanderkerken, D. Lambrechts, E. De Bruyne
P09 DARPin® molecule MP0250, a new antiangiogenic drug in multiple myeloma: An in vitro and in vivo study
K. De Veirman, L. Rao, M.A. Frassanito, V. Desantis, D. Giannico, L. di Marzo, U. Fiedler, A. Harstrick, D. Ribatti, K. Vanderkerken, A. Vacca
P08 Immunotherapy in Multiple Myeloma using alfa-galactosylceramide loaded sEVs from dendritic cells to stimulate NKT activity
S. Faict, M. Favreau, E.D.B. E., K. De Veirman, K. Maes, K. Vanderkerken, R. Schots, E. Menu
P07 Unravelling oncogenic signalling induced by JAK3 mutations in a model of T-cell acute lymphoblastic leukemia (T-ALL)
I. Govaerts, S. Degryse, C. De Bock, K. Jacobs, S. Binos, M. Dun, J. Cools
P06 Targeted single cell sequencing unravels the heterogeneity of human T-cell acute lymphoblastic leukemia samples
J. de Bie, S. Demeyer, E. Geerdens, A. Uyttebroeck, N. Boeckx, J. Cools
PP74 Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease
G. Fransolet, L. Belle, J. Somja, M. Binsfeld, P. Delvenne, P. Drion, M. Hannon, Y. Beguin, G. Ehx, F. Baron
PP73 Loss of transfer RNA U34 modifying enzymes impairs hematopoietic stem and progenitor cell differentiation and function
A. Rosu, Q. Bai, E. Ramery, M. Thiry, P. Close, F. Bureau, C. Desmet
PP72 Transcription factors and checkpoint inhibitor expression with age: predictive markers of aging?
L. Dang, K. Willard-Gallo, S. Garaud, H. Duvillier, J.N. Lodewyckx, C. Solinas, P. de Silva, M. Berehab, C. Chunyan, C. Sibille, D. Bron
PP70 The use of adipose Stromal Vascular Fraction in a Platelet-Rich Fibrin scaffold within Bisphosphonate-Related Osteonecrosis of the Jaw treatment
C. Bouland, N. Meuleman, J. Widelec, K. Kambiz, C. Voisin, L. Lagneaux, P. Philippart
PP55 Post-transfusion HbS monitoring on TOSOH G8 in variant HbA1c mode
S. van Aelst, K. Desmet, E. Nackers, D. Kieffer
PP54 Diagnosis of de novo thrombotic microangiopathy after kidney transplantation
B. Heymans, B. Sprangers, D. Dierickx
PP53 Unexplained anaemia in the Elderly: High prevalence of functional iron deficiency and underdiagnosed myelodysplasia
L. Sattar, M. Maerevoet, D. Bron, B. Cantinieaux, P. Hermans, T. Pepersack
PP52 Daratumumab: Blessing for the patient, but hell for the clinical lab
C. van der Heijden, S. Mahieu
PP51 Impact of Th17 cell population on xenogeneic graft-versus-host disease
L. Delens
PP50 Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice
G. Ehx, G. Fransolet, L. Delens, J. Muller, Y. Beguin, S. Humblet-Baron, M. Hannon, F. Baron
Top
